IP Verse

Novel Pharmaceutical Composition - EP3090730

The patent EP3090730 was granted to Novartis on Jul 3, 2024. The application was originally filed on Aug 1, 2007 under application number EP15199469A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3090730

NOVARTIS
Application Number
EP15199469A
Filing Date
Aug 1, 2007
Status
Granted And Under Opposition
Mar 8, 2024
Grant Date
Jul 3, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (8)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ELKINGTON AND FIFEJan 10, 2025ELKINGTON AND FIFEADMISSIBLE
HAMM & WITTKOPPJan 10, 2025-ADMISSIBLE
HAMM & WITTKOPPJan 10, 2025HAMM & WITTKOPPADMISSIBLE
KILBURN & STRODEJan 10, 2025KILBURN & STRODEADMISSIBLE
MAIWALDJan 10, 2025MAIWALDADMISSIBLE
ZENTIVA KSJan 10, 2025HOFFMANN EITLEADMISSIBLE
GALENICUM HEALTH SLUJan 9, 2025GALENICUM HEALTH SLUADMISSIBLE
SCORPIOJan 9, 2025SAGITTARIUSWITHDRAWN

Patent Citations (16) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS2004019190
DESCRIPTIONUS2006178518
DESCRIPTIONUS2007105824
DESCRIPTIONUS7160870
DESCRIPTIONWO0189457
DESCRIPTIONWO03098002
DESCRIPTIONWO2004096154
OPPOSITIONUS2001044474
OPPOSITIONUS2006178518
OPPOSITIONWO03098992
OPPOSITIONWO2008136843
OTHEREP1330249
OTHEREP2152237
OTHERWO2008136843
SEARCHUS2001044474
SEARCHUS2006178518

Non-Patent Literature (NPL) Citations (58) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- CLEMONS ET AL., BREAST CANCER RES, TREAGMENT, (1999), vol. 57, page 127-
DESCRIPTION- EGGER ET AL., BONE MARROW TRANSPL., (1998), vol. 22, no. 2, pages 34 - 35-
DESCRIPTION- FETSCHER ET AL., CURRENT OPINION IN HEMAT., (2000), vol. 7, pages 255 - 60-
DESCRIPTION- GAUDRON ET AL., STEM CELLS, (1999), vol. 17, pages 100 - 6-
OPPOSITION- Alan Rawle, "BASIC PRINCIPLES OF PARTICLE SIZE ANALYSIS", Malvern Technical Paper, Malvern Instruments Limited, UK, UK , (19930101), no. MRK034, pages 1 - 8, XP002772489-
OPPOSITION- Anonymous, "(429) LIGHT DIFFRACTION MEASUREMENT OF PARTICLE SIZE", US Pharmacopeia (USP 28 NF23), UNITED STATES PHARMACOPEIAL CONVENTION, INC, (20050101), vol. USP 28, no. NF 23, pages 2314 - 2317, XP009561111-
OPPOSITION- Anonymous, "(786) PARTICLE SIZE DISTRIBUTION ESTIMATION BY ANALYTICAL SIEVING", THE UNITED STATES PHARMACOPEIA (USP 28 NF 23), UNITED STATES PHARMACOPEIAL CONVENTION, INC., (20050101), vol. USP 28, no. NF 23, ISSN 0190-5384, pages 2446 - 2448, XP009561112-
OPPOSITION- Anonymous, "A basic guide to particle characterization", Malvern Instruments Limited, pages 1 - 24, (20200604), XP055701324-
OPPOSITION- Anonymous, "GUIDE TO INSPECTIONS OF ORAL SOLID DOSAGE FORMS PRE/POST APPROVAL ISSUES FOR DEVELOPMENT AND VALIDATION", FDA, FDA, URL: http://academy.gmp-compliance.org/guidemgr/files/1-2-18.PDF, XP093253712-
OPPOSITION- Anonymous, "HIGHLIGHTS OF PRESCRIBING INFORMATION - Promacta", GlaxoSmithKline, pages 1 - 21, GlaxoSmithKline, URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022291lbl.pdf, (20201117), XP055751403-
OPPOSITION- Anonymous, "ICH HARMONISED TRIPARTITE GUIDELINE SPECIFICATIONS: TEST PROCEDURESSANDDACCEPTANCE CRITERIA FOR NEW DRUG SUBSTANCESSANDDNEW DRUG PRODUCTS: CHEMICAL SUBSTANCES Q6A", INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE, INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE, (20221013), XP055970814-
OPPOSITION- Ashford M, "Bioavailability - Physicochemical and dosage form factors", Ashford M, AULTON M.E. (ED.).2, PHARMACEUTICS. THE SCIENCE OF DOSAGE FORM DESIGN ED. 2, UK, CHURCHILL LIVIGSTONE , (20020101), pages 234 - 252, 027702, ISBN 978-0-443-05517-1, XP007914455-
OPPOSITION- Bauer, Kurt H, ; Frömming, Karl-Heinz, Führer, Claus, " 2 Pulver Kapitel - passage ", Bauer, Kurt H, ; Frömming, Karl-Heinz, Führer, Claus, Kurt H. Bauer • Karl-Heinz Frömming • Claus Führer, Pharmazeutische Technologie, 4. Auflage, Georg Thieme Verlag, (19930101), pages 283 - 287, ISBN 3136925041, XP009559669-
OPPOSITION- Boris Y. Shekunov ; Pratibhash Chattopadhyay ; Henry H. Y. Tong ; Albert H. L. Chow, "Particle Size Analysis in Pharmaceutics: Principles, Methods and Applications", Pharmaceutical Research, Kluwer Academic Publishers-Plenum Publishers, NL, NL , (20061227), vol. 24, no. 2, ISSN 1573-904X, pages 203 - 227, XP019467544-
OPPOSITION- D36 - Declaration of Dr. Jan Lenz-
OPPOSITION- D37 - DECLARATION OF DR. EDGAR JOHN-
OPPOSITION- D37 - Letter from Novartis of 21.09.2021-
OPPOSITION- D38 - Opposition against EP3090730 Experimental report concerning SEM studies of eltrombopag olamine particles-
OPPOSITION- D5 - T1772/09-
OPPOSITION- D6 - T3192/19-
OPPOSITION- Deodatt A Wadke, Abu T M Serajuddin, Harold Jacobson, "CHAPTER 1: Preformulation Testing", Pharmaceutical Dosage Forms Tablets Volume 1, US , Marcel Dekker , (19890101), pages 1 - 73, ISBN 978-0-8247-8044-9, XP009184711-
OPPOSITION- Emea, "ICH Topic Q 6 A - Specifications: test procedures and acceptance criteria for new drug substances and new drug products: chemical substances", CPMP/ICH/367/96, (20000501), pages 1 - 32, XP055966494-
OPPOSITION- Fiese E. F., Hagen, Lachman, Lieberman, Kanig, "Preformulation", The Theory and Practice of Industrial Pharmacy. 3re ed., Varghese Publishing House, (19870101), pages 171 - 197, 298-303, XP093118740-
OPPOSITION- "Guidance for Industry Dissolution Testing of Immediate Release Solid Oral Dosage Forms", FDA, FDA, URL: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm070237.pdf, (20160229), XP055253855-
OPPOSITION- Hofmann Michael Peter, "Physikalische Charakterisierung von Calciumphosphat-Pulvern zur Einstellung von Prozessparametern für die Herstellung von Knochenzement", Doctoral Dissertation, Julius-Maximilian-Universität Würzburg, (20030101), XP093253739-
OPPOSITION- John Staniforth, "Chapter 10: Particle-size Analysis", PHARMACEUTICS: THE SCIENCE OF DOSAGE FORM DESIGN, Second Edition, UK, Elsevier , (20020101), pages 152 - 165, ISBN 0-443-05517-3, XP093141669-
OPPOSITION- John Staniforth, "Chapter 11: Particle-size reduction", John Staniforth, M.E. Aulton, PHARMACEUTICS: THE SCIENCE OF DOSAGE FORM DESIGN, Second Edition, UK, Elsevier , (20020101), pages 166 - 173, ISBN 0-443-05517-3, XP009559656-
OPPOSITION- John Staniforth, "Chapter 12: Particle-size separation", John Staniforth, M.E. Aulton, Pharmaceutics THE SCIENCE OF DOSAGE FORM DESIGN; 2nd Edition, Churchill Livingstone, (20020101), pages 174 - 180, ISBN 0-443-05517-3, XP009559655-
OPPOSITION- Joseph P. Remington, "Dissolution", Joseph P. Remington, Gennaro Alfonso R., Remington: the science and practice of pharmacy, Easton, Pennsylvania , Mack Publishing Company , (19950101), page 2pp, 595, ISBN 978-0-912734-04-0, XP055282825-
OPPOSITION- Kumar Vijay , Gilbert S.Banker, "Maillard Reaction and Drug Stability", Maillard Reactions in Chemistry, Food, and Health, (20050101), pages 20 - 27, XP093190032-
OPPOSITION- Lachman Leon, Herbert A. Lieberman, Joseph L. Kanig, "Factors Affecting Drug Absorption", The Theory and Practice of Industrial Pharmacy, VARGHESE PUBLISHING HOUSE, (19870101), page 221, XP093186868-
OPPOSITION- Leon Lachman, Herbert A Lieberman and Joseph L Kanig, "Factors Affecting Drug Absorption", THEORY AND PRACTICE OF INDUSTRIAL PHARMACY third edition, Philadelpia , Lea & Febiger , (19860101), pages 221 - 222, XP003032295-
OPPOSITION- M. E. Aulton, M. Ashford, "Bioavailability - physicochemical and dosage form factors // Tablet Manufacturing", Aulton's Pharmaceutics, The Design and Manufacture of Medicines, 3rd edition, CHURCHILL LIVINGSTONE ELSEVIER, (20070101), pages 286 - 449, ISBN 978-0-443-10107-6, XP055308287-
OPPOSITION- Milo Gibaldi, "Gastrointestinal Absorption - Physicochemical Considerations", Biopharmaceutics and Clinical Pharmacokinetics, fourth edition, Lea& Febiger , (19910101), page 51, ISBN 978-0-8121-1346-4, XP055355462-
OPPOSITION- Rawle, Alan, "Basic principles of particle size analysis", Technical Paper, Malvern Instruments Ltd., UK, UK, (20020710), pages 1 - 24, XP009561113-
OPPOSITION- Terence Allen, "Chapter 3: Particle size analysis by image analysis", Terence Allen, TERENCE ALLEN, Particle Size Measurement, Volume 1, Powder sampling and particle size measurement, Fifth edition, Chapman & Hall, (19970101), pages 112 - 155, ISBN 0412729504, XP009559657-
OPPOSITION- Umesh V. Banakar, "Passage; Chapter 5: Factors That Influence Dissolution Testing", Pharmaceutical Dissolution Testing, US , Marcel Dekker Inc. , (19920101), pages 138 - 141, ISBN 0-8247-8567-3, XP055648904-
OPPOSITION- W.A. Ritschel, A. Bauer-Brandl, "Direkttablettierbare Mischungen", Die Tablette Handbuch der Entwicklung, Herstellung und Qualitätssicherung, Edito Cantor Verlag , (20020101), pages 252 - 260, ISBN 978-3-87193-228-1, XP008180046-
OPPOSITION- Snorek Sharon M., Bauer John F., Chidambaram Nallaperumal, Doub William H., Duffy Eric P., Etzler Frank M., Kelly Richard N., Lane Justin J., Mueller Ronald L., Prasanna Hullahalli R., Pujara Chetan P., Reif Van D., Scarlett Brian, Stowell Joseph G., Toma Pascal H., "PQRI Recommendations on Particle-Size Analysis of Drug Substances Used in Oral Dosage forms", Journal of pharmaceutical sciences, Elsevier Inc, Hoboken, Hoboken, (20070601), vol. 96, no. 6, doi:10.1002/jps.20822, ISSN 0022-3549, pages 1451 - 1467, XP055955545
OPPOSITION- FINCHER J H, "PARTICLE SIZE OF DRUGS AND ITS RELATIONSHIP TO ABSORPTION AND ACTIVITY", Journal of pharmaceutical sciences, Elsevier Inc, Hoboken, Hoboken, (19681101), vol. 57, no. 11, doi:10.1002/jps.2600571102, ISSN 0022-3549, pages 1825 - 1835, XP009048256
OPPOSITION- Heekyu Choi, Woong Lee, Dong-Uk Kim, Shalendra Kumar, Jonghak Ha, Seongsoo Kim, Jungeun Lee, "A comparative study of particle size analysis in fine powder: The effect of a polycomponent particulate system", Korean Journal of Chemical Engineering, The Korean Institute of Chemical Engineers, (20090101), vol. 26, no. 1, doi:10.1007/s11814-009-0052-7, ISSN 02561115, pages 300 - 305, XP055144956
OPPOSITION- Mosharraf Mitra, Nyström Christer, "The effect of particle size and shape on the surface specific dissolution rate of microsized practically insoluble drugs", International Journal of Pharmaceutics, Elsevier, AMSTERDAM, NL, AMSTERDAM, NL, (19950801), vol. 122, no. 1-2, doi:10.1016/0378-5173(95)00033-F, ISSN 0378-5173, pages 35 - 47, XP093253717
OPPOSITION- Takagi Toshihide, Ramachandran Chandrasekharan, Bermejo Marival, Yamashita Shinji, Yu Lawrence X., Amidon Gordon L., "A Provisional Biopharmaceutical Classification of the Top 200 Oral Drug Products in the United States, Great Britain, Spain, and Japan", Molecular Pharmaceutics, American Chemical Society, US, US , (20061201), vol. 3, no. 6, doi:10.1021/mp0600182, ISSN 1543-8384, pages 631 - 643, XP093253789
OPPOSITION- C. D. Melia, S. S. Davis, "Review article: mechanisms of drug release from tablets and capsules. 2. Dissolution", Alimentary Pharmacology & Therapeutics, BLACKWELL SCIENTIFIC PUBLICATIONS LTD., CAMBRIDGE., GB, GB , (19891201), vol. 3, no. 6, doi:10.1111/j.1365-2036.1989.tb00243.x, ISSN 0269-2813, pages 513 - 525, XP055523028
OPPOSITION- Julian M. Jenkins, Daphne Williams, Yanli Deng, Joanne Uhl, Valerie Kitchen, David Collins, and Connie L. Erickson-Miller, "Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist", Blood, W.B. Saunders, AMSTERDAM, NL, AMSTERDAM, NL, (20070601), vol. 109, no. 11, doi:10.1182/blood-2006-11-057968, ISSN 0006-4971, pages 4739 - 4741, XP008147185
OPPOSITION- Imdad Husen Mukeri, M Sunitha Reddy, "Approaches to Improve bioavailability and oral absorption of low water-soluble drug by self- emulsifying drug delivery system", GSC Biological and Pharmaceutical Sciences, vol. 22, no. 1, doi:10.30574/gscbps.2023.22.1.0034, ISSN 2581-3250, pages 215 - 229, XP093253797
OTHER- Anonymous, "USP 28 NF 23- Passage", USP 28 NF 23, (20050101), pages 2314 - 2317,2446-2448, XP093141655-
OTHER- Anonymous, "Whitepaper -A basic quide to particle characterization", Malvern Instruments Ltd., (20150101), pages 1 - 24, XP093141716-
OTHER- A. RITSCHEL et al., Die Tablette Handbuch der Entwicklung, Herstellung und Qualitätssicherung, Editio Cantor Verlag Aulendorf, (20020000), page 2p, 212, XP055648889-
OTHER- Aulton Michael E., "Pharmaceutics The Science of Dosage Form Design-Passage", Pharmaceutics The Science of Dosage Form Design- Second edition, (20020101), pages 152 - 165, XP093141669-
OTHER- Bauer Kurt H., "Pharmazeutische Technologie-Passage", Pharmazeutische Technologie, Georg Thieme Verlag, (19930101), pages 283,286 - 287, XP093141662-
OTHER- EMEA, "ICH Topic Q 6 A - Specifications: test procedures and acceptance criteria for new drug substances and new drug products: chemical substances", (20000500), pages 1 - 32, XP055211303-
OTHER- Guidance for Industry Dissolution Testing of Immediate Release Solid Oral Dosage Forms, (19970800), XP055253855-
OTHER- H.A. Liebermann Et Al., "Pharmaceutical Dosage Forms", H.A. Liebermann Et Al., LIEBERMAN H.A.; LACHMAN L.; SCHAWARTZ J.B., Pharmaceutical Dosage Forms: Tablets, US , Marcel Dekker , (19890101), pages 5 - 6, ISBN 978-0-8247-8044-9, XP055308395-
OTHER- LIEBERMAN, LACHMAN et al., Pharmaceutical Dosage Forms, Tablets, (19890000), vol. 1, page 5, 6, 22, 23, XP009184711-
OTHER- U. BANAKAR, Pharmaceutical Dissolution Testing, Marcel Decker, (19920000), vol. 49, pages 138 - 141, XP055648904-
OTHER- B.Y. SHEKUNOV et al., "Particle Size Analysis in Pharmaceutics: Principles, Methods and Applications", Pharmaceutical Research, (20070200), vol. 24, no. 2, pages 203 - 227, XP055572217
SEARCH- Bauer; F�hrer, Lehrbuch der pharmazeutischen Technologie, Stuttgart, Wiss.Verl.-Ges., (19990101), pages 445 - 446, ISBN 3-8047-1700-4, XP002665806 [A] 1-46 * the whole document *-

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents